Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 11 Jan 2017 Status changed from recruiting to discontinued.
- 09 Sep 2016 Planned End Date changed from 1 Sep 2017 to 1 Jul 2017.
- 09 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2017.